Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Charles River Laboratories to Present at Raymond James and Barclays Investor Conferences

CRL

Charles River Laboratories to Present at Raymond James and Barclays Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:

  • Raymond James 40th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 5th, at 9:50 a.m. ET; and
  • Barclays Global Healthcare Conference in Miami, Florida on Wednesday, March 13th, at 10:15 a.m. ET.

Management will present an overview of Charles River’s strategic focus and business developments.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com